Dark

Check out our Level2View

ENOB
Enochian Biosciences Inc. Common Shares
stock NASDAQ

Inactive

Aug 4, 2023

0.7000USD0.000%(0.0000)88,381

Pre-market

0.00USD-100.000%(-0.70)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Dec 3, 2021

07:04AM EST Enochain BioSciences Highlights Presentation At World Vaccine Conference Related To Treatment Of Solid Tumors Benzinga

07:00AM EST Enochian BioSciences Announces Scientific Presentation at World GlobeNewswire Inc

Oct 18, 2021

07:04AM EDT Enochian BioSciences Announces Completion Of FDA Pre-IND For A Potential Cure For HIV Benzinga

07:00AM EDT Enochian BioSciences Announces the Successful Completion of GlobeNewswire Inc

Oct 15, 2021

06:00PM EDT (NASDAQ: ENOB) Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that Dr. Peter Piot has resigned as Chairperson of the Respiratory Diseases Scientific Advisory Board due to important responsibilities advising a major governmental organization on COVID-19 that creates a conflict. GlobeNewswire Inc

Oct 12, 2021

06:00PM EDT (NASDAQ: ENOB) Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference. GlobeNewswire Inc

Sep 27, 2021

07:11AM EDT Enochian BioSciences Completes FDA Pre-IND For Potential Cure For Hepatitis B Virus Infection RTTNews

07:04AM EDT Enochian BioSciences Announces Its Completion Of FDA Pre-IND Process For ENOB-HB-01 Benzinga

07:00AM EDT Enochian BioSciences Announces ItsSuccessful GlobeNewswire Inc

Sep 13, 2021

07:00AM EDT Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference. GlobeNewswire Inc

Aug 30, 2021

07:00AM EDT Distinguished Scientific and Public Health Leaders to Join GlobeNewswire Inc

Aug 23, 2021

10:18AM EDT Distinguished Scientific and Clinical Leader to Join Enochian GlobeNewswire Inc

Jul 20, 2021

07:16AM EDT Enochian BioSciences Names Mark Dybul As CEO RTTNews

07:10AM EDT Enochian BioSciences Names Dr. Mark Dybul CEO Benzinga

07:00AM EDT (NASDAQ: ENOB) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Honorable Mark Dybul, M.D. has been named as Chief Executive Officer (CEO). GlobeNewswire Inc

Jul 12, 2021

08:37AM EDT Enochian Stock Is Trading Higher On FDA Acceptance of Pre-IND Request For Hepatitis B Program Benzinga

07:10AM EDT Enochian BioSciences Announces FDA Acceptance Of Pre-IND Request For Potential Cure For Hepatitis B Virus Infection RTTNews

07:02AM EDT (NASDAQ: ENOB) Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments are expected this Fall. GlobeNewswire Inc

Jun 30, 2021

07:10AM EDT Enochian BioSciences Highlights Scientific Presentation Of Elimination Of HBV In Mice With No Evident Toxicity Benzinga

07:00AM EDT Enochian BioSciences Announces Scientific Presentation of GlobeNewswire Inc

Jun 21, 2021

08:03AM EDT Enochian BioSciences Stock Is Trading Higher After In-Licensing COVID-19, Influenza Inhaled Treatment Technology Benzinga

07:04AM EDT Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhaled Treatment and Prevention Technology Benzinga

07:00AM EDT Enochian BioSciences Announces Acquisition of Exclusive License GlobeNewswire Inc

Jun 15, 2021

09:08AM EDT Seraph Research Institute Highlights Will Move Forward With First Stage Of Approval Process For HIV Candidate; Press Release Notes Proprietary Technology For Pre-Investigational New Drug Meeting Licensed To Enochian BioSciences Benzinga

09:06AM EDT Pioneering Research Institute In Los Angeles Moves One Step Closer To Finding A PR Newswire

08:07AM EDT The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda Benzinga

Jun 14, 2021

03:00PM EDT UPDATE: Enochian BioSciences Offering Priced $7.50/Share Benzinga

02:53PM EDT Enochian BioSciences Announces $29 Million Registered Direct GlobeNewswire Inc

02:47PM EDT Mid-Afternoon Market Update: Dow Tumbles 250 Points; Enochian Biosciences Shares Spike Higher Benzinga

12:25PM EDT Mid-Day Market Update: Nasdaq Rises Over 50 Points; Washington Prime Group Shares Plunge Benzinga

10:29AM EDT Mid-Morning Market Update: Markets Mostly Lower; Accenture To Acquire German Engineering Company Benzinga

08:22AM EDT Benzinga Pro's Top 5 Stocks To Watch For Monday, June 14, 2021: CRSR, RIDE, ITOS, ATXI, ENOB Benzinga

07:03AM EDT Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential HIV Cure Benzinga

07:00AM EDT Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential functional cure or treatment of HIV. Written comments are expected this Fall. GlobeNewswire Inc

May 12, 2021

08:06AM EDT A Promising Approach To HIV Cell Therapy, With Exciting Preliminary Results, PR Newswire

08:00AM EDT Enochian BioSciences announces Scientific Presentation of a Person GlobeNewswire Inc

Mar 25, 2021

05:59AM EDT Enochian BioSciences Shares Rise 58% Premarket After Co Announces Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy Benzinga

Mar 24, 2021

06:00PM EDT Seraph Research Institute and Enochian GlobeNewswire Inc

Feb 22, 2021

05:15PM EST Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference. GlobeNewswire Inc

Sep 10, 2020

12:50AM EDT (NASDAQ: ENOB) Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors on its innovative HIV, Hepatitis B and Oncology platforms at the H.C. Wainwright 22nd Annual Global Investment Conference. GlobeNewswire Inc

Jul 27, 2020

08:00AM EDT Drs. Carol Brosgart, Peter Revill and Fabien Zoulim will advise on development of a cure for Hepatitis B GlobeNewswire Inc

Share